Company news
Denali Therapeutics Inc. news in 2023
Denali Therapeutics Inc.'s news releases, calls and decks from 2023, newest first.
Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
November 6, 2023
Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV: IDS) in MPS II (Hunter Syndrome) at SSIEM 2023
August 29, 2023
Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
August 7, 2023
Flagship Pioneering Unveils Empress Therapeutics to Revolutionize Drug Discovery by Applying the Power of Genetics to Identify Small Molecule Drugs
June 20, 2023
Denali Therapeutics Announces Robust Reduction in Neurofilament Light (NfL) with DNL310 (ETV: IDS) Treatment in MPS II (Hunter Syndrome)
June 19, 2023
Denali Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
May 7, 2023
Biogen Exercises Option with Denali to Develop and Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta
April 11, 2023
Denali Therapeutics Announces New DNL343 (eIF2B Agonist) Phase 1b Data in ALS To Be Presented at the Upcoming AAN Annual Meeting
April 9, 2023
Denali Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
February 26, 2023
Denali Therapeutics Announces New Interim Data from DNL310 Phase 1/2 Study for MPS II and DNL126 Preclinical Data for MPS IIIA at WORLDSymposium™
February 21, 2023
Denali Therapeutics Announces Presentations on Enzyme Transport Vehicle (ETV) Development Programs for MPS Diseases at the Upcoming WORLDSymposium™
February 14, 2023
Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in Multiple Sclerosis by Sanofi
January 24, 2023
Denali Therapeutics Announces Key Anticipated 2023 Milestones for Its Therapeutic Portfolio for Neurodegeneration and Lysosomal Storage Diseases
January 8, 2023
Decks in 2023
- Investor Presentation (March 2023)
Investor deck · 41 slides · March 2023